Scarica l'app Stockscreener
18.50
12.05%
1.99
Mbx Biosciences Inc Borsa (MBX) Ultime notizie
MBX Biosciences (NYSE:MBX) Shares Up 6.5%Here's Why - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Gap DownHere's What Happened - MarketBeat
MBX Biosciences completes phase 1 trial of diabetes drug - Investing.com India
MBX Biosciences (NYSE:MBX) Shares Gap UpWhat's Next? - MarketBeat
MBX Biosciences Announces Last Subject Last Visit in Phase - GlobeNewswire
Mbx Biosciences, Inc. Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia - Marketscreener.com
MBX Biosciences (NYSE:MBX) Reaches New 12-Month Low – Here’s Why - Defense World
MBX Biosciences (NYSE:MBX) Sets New 1-Year LowTime to Sell? - MarketBeat
MBX Biosciences: Decent Potential For Lead Indication, But Need More Data (NASDAQ:MBX) - Seeking Alpha
Behind the Bell: MBX Biosciences - Nasdaq
MBX Biosciences Reports Q3 2024 Financial Progress - MSN
Wellington Management Group LLP Acquires New Stake in MBX Biosci - GuruFocus.com
MBX Biosciences Inc. (MBX) Quarterly 10-Q Report - Quartzy
MBX Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
MBX Biosciences Secures $251M in IPO, Advances Clinical Pipeline with Strong Cash Position | MBX Stock News - StockTitan
MBX Biosciences (NYSE:MBX) Shares Up 8.2%Time to Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Up 6.8%Should You Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Sets New 52-Week LowTime to Sell? - MarketBeat
MBX Biosciences to Participate in Upcoming November Investor Conferences - The Manila Times
MBX Biosciences (NYSE:MBX) Shares Down 4.5%Here's What Happened - MarketBeat
MBX Biosciences sets IPO terms with plans to raise up to $136 million - MSN
MBX Biosciences, Inc.'s (NYSE:MBX) Quiet Period To End on October 23rd - MarketBeat
MBX Biosciences, Inc.’s Quiet Period Set To Expire on October 23rd (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Stock Price Down 4%Here's Why - MarketBeat
MBX Bio drops despite bullish views on Street - MSN
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - BNN Bloomberg
MBX Biosciences (NYSE:MBX) Shares Up 4.6%Here's What Happened - MarketBeat
MBX Biosciences earns Buy rating at three investment firms - MSN
MBX Bio stock drops despite bullish initiations (NASDAQ:MBX) - Seeking Alpha
Guggenheim bullish on MBX Biosciences stock, driven by MBX 2109 potential - Investing.com Canada
MBX Biosciences outlook solid with JPMorgan's overweight rating, eyes key catalysts in next 12 months - Investing.com India
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements - Investing.com India
MBX Biosciences earns Buy rating at three investment firms By Investing.com - Investing.com Canada
Guggenheim Begins Coverage on MBX Biosciences (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Now Covered by JPMorgan Chase & Co. - MarketBeat
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements By Investing.com - Investing.com South Africa
MBX Biosciences (NYSE:MBX) Stock Price Down 3.5%Should You Sell? - MarketBeat
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ - GlobeNewswire
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting - Yahoo Finance
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):